

Prolong Pharmaceuticals, Interview Released Ahead of Keynote Address at Biosimilars 2017 Summit

SMi Group release interview with Glenn Kazo, President and Chief Operating Officer from Prolong Pharmaceuticals

LONDON, ENGLAND, UNITED KINGDOM, July 25, 2017 /EINPresswire.com/ -- SMi Group have released an interview with Glenn Kazo, President and Chief Operating Officer from Prolong Pharmaceuticals, ahead of his presentation at the 8th annual industry summit on [Biosimilars & Biobetters](#) this September.

Prolong Pharmaceuticals is a privately held company with portfolio of hematology and oncology products in clinical development. With over 25 years of experience, Glenn Kazo has been very active in the advancement of Biosimilars and BioBettters, both as an industry speaker and in leading several drug development programs. Throughout his career, Glenn has continued an active consulting practice, advising biopharma clients and venture capital firms on corporate strategy and development.

With a focus on Biobetters, his presentation will explore developing the next generation anti-neuropenic factor.

Neulasta is one of the most desirable targets for biosimilar development. Glen's talk will discuss ongoing technical and market challenges to biosimilar versions of Neulasta, neutropenia prevention vs treatment; and the commercial approach to developing ANF-RhoTM.

“

...companies are now finding out that regulators and customers hold a very high standard of 'similar' and an even higher standard for "interchangeable"

Glenn Kazo, President and COO, Prolong Pharmaceuticals

In the run-up to the event, SMi Group caught up with Glen to discuss in industry developments and on-going challenges in Biosimilars.

“Beginning in 2012, I gave a series of talks called Why 'BioDifferent Equals BioBetter.' The underlying theme was that it is much easier to prove that products are different rather than to prove that products are similar. It wasn't a popular concept – but companies are now finding out that regulators and customers hold a very high standard of 'similar' and an even higher standard for "interchangeable.”

The full interview is available to read in the event [download centre](#) with further Q&A's from Celltrion and Bioceros.

The poster for the SMi's 8th annual event, 'Biosimilars & Biobetters', is set against a blue background. It features a close-up of two red and white capsules. A pink box in the lower right corner displays the dates '27 - 28 SEPT 2017'. The event location, 'Holiday Inn Kensington Forum, London UK', is listed below the title. The website 'www.biosimilars-europe.com' is at the bottom, and the event name 'Biosimilars & Biobetters 2017' is at the very bottom.

SMi's 8th annual event...
Biosimilars & Biobetters
Holiday Inn Kensington Forum,
London UK
27 - 28
SEPT
2017
www.biosimilars-europe.com
Biosimilars & Biobetters 2017

SMi's 8th Annual Biosimilars & Biobetters event will take place on 27th and 28th September 2017 at the Holiday Inn Kensington Forum, London UK.

More information and a detailed agenda featuring talks from Boehringer Ingelheim, Celltrion Healthcare, Gedeon Richter, Teva Pharmaceuticals, Merck Group, QuintilesIMS and the Norwegian Medicines Agency is available at www.biosimilars-europe.com

--end --

Contact Information:

For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
[email us here](mailto:tarri@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.